The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications

doi:10.1093/neuonc/noab120

Editorial

. 2021 Aug 2;23(8):1215-1217.

doi: 10.1093/neuonc/noab120.

The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications

Patrick Y Wen¹, Roger J Packer^{2

3}

Affiliations

¹ Center for Neuro-Oncology, Dana-Farber Cancer Institute, Division of Neuro-Oncology, Department of Neurology, Brigham and Woman's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
² Center for Neuroscience and Behavioral Medicine, Brain Tumor Institute, Gilbert Family Neurofibromatosis Institute, Children's National Hospital, Washington, DC, USA.
³ Departments of Neurology and Pediatrics at the George Washington University, Washington, DC, USA.

PMID: 34185090
PMCID: PMC8328017
DOI: 10.1093/neuonc/noab120

Editorial

The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications

Patrick Y Wen et al. Neuro Oncol. 2021.

. 2021 Aug 2;23(8):1215-1217.

doi: 10.1093/neuonc/noab120.

Authors

Patrick Y Wen¹, Roger J Packer^{2

3}

Affiliations

¹ Center for Neuro-Oncology, Dana-Farber Cancer Institute, Division of Neuro-Oncology, Department of Neurology, Brigham and Woman's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
² Center for Neuroscience and Behavioral Medicine, Brain Tumor Institute, Gilbert Family Neurofibromatosis Institute, Children's National Hospital, Washington, DC, USA.
³ Departments of Neurology and Pediatrics at the George Washington University, Washington, DC, USA.

PMID: 34185090
PMCID: PMC8328017
DOI: 10.1093/neuonc/noab120

No abstract available

PubMed Disclaimer

Comment on

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. Louis DN, et al. Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106. Neuro Oncol. 2021. PMID: 34185076 Free PMC article. Review.

Cited by

Application of a risk score model based on glycosylation-related genes in the prognosis and treatment of patients with low-grade glioma.
Zou B, Li M, Zhang J, Gao Y, Huo X, Li J, Fan Y, Guo Y, Liu X. Zou B, et al. Front Immunol. 2024 Oct 9;15:1467858. doi: 10.3389/fimmu.2024.1467858. eCollection 2024. Front Immunol. 2024. PMID: 39445005 Free PMC article.
Evaluation of Single and Combined Temozolomide and Doxorubicin Treatment Responses in Low- and High-Grade Glioma In Vitro.
Staicu GA, Tataranu LG, Tache DE, Popescu SO, Artene SA, Danoiu S, Sfredel V, Barcan EN, Baloi SC, Dricu A. Staicu GA, et al. Cureus. 2024 Aug 15;16(8):e66928. doi: 10.7759/cureus.66928. eCollection 2024 Aug. Cureus. 2024. PMID: 39280423 Free PMC article.
The anterior gradient homologue 2 (AGR2) co-localises with the glucose-regulated protein 78 (GRP78) in cancer stem cells, and is critical for the survival and drug resistance of recurrent glioblastoma: in situ and in vitro analyses.
Hussein D, Alsereihi R, Salwati AAA, Algehani R, Alhowity A, Al-Hejin AM, Schulten HJ, Baeesa S, Bangash M, Alghamdi F, Cross R, Al Zughaibi T, Saka M, Chaudhary A, Abuzenadah A. Hussein D, et al. Cancer Cell Int. 2022 Dec 8;22(1):387. doi: 10.1186/s12935-022-02814-5. Cancer Cell Int. 2022. PMID: 36482387 Free PMC article.
HADHA promotes glioma progression by accelerating MDM2-mediated p53 ubiquitination.
Chen R, Chen H, Hu C. Chen R, et al. Cancer Gene Ther. 2024 Sep;31(9):1380-1389. doi: 10.1038/s41417-024-00801-8. Epub 2024 Jul 22. Cancer Gene Ther. 2024. PMID: 39039194
Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation.
Orzan F, De Bacco F, Lazzarini E, Crisafulli G, Gasparini A, Dipasquale A, Barault L, Macagno M, Persico P, Pessina F, Bono B, Giordano L, Zeppa P, Melcarne A, Cassoni P, Garbossa D, Santoro A, Comoglio PM, Indraccolo S, Simonelli M, Boccaccio C. Orzan F, et al. Clin Cancer Res. 2023 Apr 3;29(7):1252-1266. doi: 10.1158/1078-0432.CCR-22-2903. Clin Cancer Res. 2023. PMID: 36648487 Free PMC article.

See all "Cited by" articles

References

1. Louis DN, Perry A, Wesseling P, et al. . The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–1251. - PMC - PubMed
1. Jones DTW, Kieran MW, Bouffet E, et al. . Pediatric low-grade gliomas: next biologically driven steps. Neuro Oncol. 2018;20(2):160–173. - PMC - PubMed
1. Reinhardt A, Stichel D, Schrimpf D, et al. . Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathol. 2018;136(2):273–291. - PubMed
1. Fukuoka K, Mamatjan Y, Tatevossian R, et al. . Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas. Neuro Oncol. 2020;22(10):1474–1483. - PMC - PubMed
1. Baroni L, Sundaresan L, Heled A, et al. . Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. Neuro Oncol. 2021;23(8):1372–1381. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources

[1] Louis DN, Perry A, Wesseling P, et al. . The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–1251. - PMC - PubMed

[2] Louis DN, Perry A, Wesseling P, et al. . The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–1251. - PMC - PubMed

[3] Jones DTW, Kieran MW, Bouffet E, et al. . Pediatric low-grade gliomas: next biologically driven steps. Neuro Oncol. 2018;20(2):160–173. - PMC - PubMed

[4] Jones DTW, Kieran MW, Bouffet E, et al. . Pediatric low-grade gliomas: next biologically driven steps. Neuro Oncol. 2018;20(2):160–173. - PMC - PubMed

[5] Reinhardt A, Stichel D, Schrimpf D, et al. . Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathol. 2018;136(2):273–291. - PubMed

[6] Reinhardt A, Stichel D, Schrimpf D, et al. . Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathol. 2018;136(2):273–291. - PubMed

[7] Fukuoka K, Mamatjan Y, Tatevossian R, et al. . Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas. Neuro Oncol. 2020;22(10):1474–1483. - PMC - PubMed

[8] Fukuoka K, Mamatjan Y, Tatevossian R, et al. . Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas. Neuro Oncol. 2020;22(10):1474–1483. - PMC - PubMed

[9] Baroni L, Sundaresan L, Heled A, et al. . Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. Neuro Oncol. 2021;23(8):1372–1381. - PMC - PubMed

[10] Baroni L, Sundaresan L, Heled A, et al. . Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. Neuro Oncol. 2021;23(8):1372–1381. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications

Affiliations

The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications

Authors

Affiliations

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources